Katherine A. Thornton

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

27h-index5.9kcitations159works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(102), Cancer Immunotherapy and Biomarkers(37), Vascular Tumors and Angiosarcomas(29), Lung Cancer Treatments and Mutations(23), Bone Tumor Diagnosis and Treatments(19)

Publications159 total

Glycosylated extracellular matrix drives immune suppression by controlling T cell movement, macrophage phenotype, and macrophage-T cell crosstalk in triple negative breast cancer
2025Open Access
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
JCO oncology advances.·2025· 2 citedOpen Access
Functional somatic symptoms in Emergency Department frequent presenters
BMC Emergency Medicine·2024· 2 citedOpen Access
Harmonization of the Upfront Osteosarcoma Treatment Paradigm for Adolescents and Young Adults
Journal of Adolescent and Young Adult Oncology·2024Open Access
Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study
Blood·2023· 40 cited
TABLE 2 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
TABLE 3 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
Supplementary Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
TABLE 4 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
Supplementary Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
TABLE 4 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
TABLE 3 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
TABLE 1 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
TABLE 2 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
TABLE 1 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
2023Open Access
Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
Cancer Research Communications·2023· 11 citedOpen Access
Supplementary Figure 2 from Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor
2023Open Access
Supplementary Figure 1 from Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Mrinal M. Gounder(11), Sujana Movva(9), William D. Tap(9), Benjamin A. Nacev(8), Evan Rosenbaum(8), Sandra P. D’Angelo(8), Mark A. Dickson(8), Ciara M. Kelly(8), Ping Chi(7), Mary Louise Keohan(7), Jason E. Chan(6), Samuel Singer(6), Chandrajit P. Raut(5), Andrew J. Wagner(5), Cristina R. Antonescu(5), Emily K. Slotkin(5), Viswatej Avutu(5), Christian F. Meyer(5), Michael A. Choti(4), Luis A. Díaz(4)